{"id":"https://openalex.org/W2063663785","doi":"https://doi.org/10.1177/2042098614560736","title":"New antiepileptic medication linked to blue discoloration of the skin and eyes","display_name":"New antiepileptic medication linked to blue discoloration of the skin and eyes","publication_year":2014,"publication_date":"2014-11-20","ids":{"openalex":"https://openalex.org/W2063663785","doi":"https://doi.org/10.1177/2042098614560736","mag":"2063663785","pmid":"https://pubmed.ncbi.nlm.nih.gov/25642319","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4308410"},"language":"en","primary_location":{"id":"doi:10.1177/2042098614560736","doi":"https://doi.org/10.1177/2042098614560736","is_oa":false,"landing_page_url":"https://doi.org/10.1177/2042098614560736","pdf_url":null,"source":{"id":"https://openalex.org/S2764500180","display_name":"Therapeutic Advances in Drug Safety","issn_l":"2042-0986","issn":["2042-0986","2042-0994"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Drug Safety","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4308410/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005637423","display_name":"Sarah L. Clark","orcid":"https://orcid.org/0009-0001-3452-1563","observed_orcids":["https://orcid.org/0009-0001-3452-1563"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Clark","raw_affiliation_strings":["Department of Pharmacy Mayo Clinic, 200 First Street SW Rochester Minnesota 55905, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy Mayo Clinic, 200 First Street SW Rochester Minnesota 55905, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002692624","display_name":"Alexandra Antell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131228","display_name":"Adventist Health Glendale","ror":"https://ror.org/03kr0f697","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210131228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexandra Antell","raw_affiliation_strings":["Glendale Adventist Medical Center Department of Pharmaceutical Sciences 1509 Wilson Terrace Glendale, CA 91206, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glendale Adventist Medical Center Department of Pharmaceutical Sciences 1509 Wilson Terrace Glendale, CA 91206, USA","institution_ids":["https://openalex.org/I4210131228"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5055578879","display_name":"Kimberly Kaufman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kimberly Kaufman","raw_affiliation_strings":["Department of Pharmacy Mayo Clinic 200 First Street SW Rochester, MN 55905"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy Mayo Clinic 200 First Street SW Rochester, MN 55905","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2800,"currency":"USD","value_usd":2800},"apc_paid":null,"fwci":0.525,"has_fulltext":false,"cited_by_count":69,"citation_normalized_percentile":{"value":0.40682891,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"6","issue":"1","first_page":"15","last_page":"19"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9106000065803528,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9106000065803528,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.04089999943971634,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.031700000166893005,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ezogabine","display_name":"ezogabine","score":1.0},{"id":"https://openalex.org/keywords/antiepileptic-drugs","display_name":"antiepileptic drugs","score":0.8360000252723694},{"id":"https://openalex.org/keywords/blue-discoloration","display_name":"blue discoloration","score":0.6930000185966492},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5440000295639038},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8370000123977661},{"id":"https://openalex.org/keywords/focal-seizures","display_name":"focal seizures","score":0.7459999918937683},{"id":"https://openalex.org/keywords/adjunctive-antiepileptic-therapy","display_name":"adjunctive antiepileptic therapy","score":0.6850000023841858},{"id":"https://openalex.org/keywords/boxed-warning","display_name":"black box warning","score":0.6370000243186951},{"id":"https://openalex.org/keywords/risk-evaluation-and-mitigation-strategy","display_name":"risk evaluation and mitigation strategy","score":0.6809999942779541},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.37700000405311584}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.921605110168457},{"id":"https://openalex.org/C3018890749","wikidata":"https://www.wikidata.org/wiki/Q204711","display_name":"Food and drug administration","level":2,"score":0.5874945521354675},{"id":"https://openalex.org/C2994127763","wikidata":"https://www.wikidata.org/wiki/Q576618","display_name":"Antiepileptic drug","level":3,"score":0.5426855087280273},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.49630576372146606},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4929642677307129},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4638493061065674},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.41949909925460815},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.3741115927696228},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.351077675819397},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.26555782556533813},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.24923893809318542},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.1733865737915039},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.14083963632583618}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1177/2042098614560736","doi":"https://doi.org/10.1177/2042098614560736","is_oa":false,"landing_page_url":"https://doi.org/10.1177/2042098614560736","pdf_url":null,"source":{"id":"https://openalex.org/S2764500180","display_name":"Therapeutic Advances in Drug Safety","issn_l":"2042-0986","issn":["2042-0986","2042-0994"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Drug Safety","raw_type":"journal-article"},{"id":"pmid:25642319","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25642319","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic advances in drug safety","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4308410","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4308410/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ther Adv Drug Saf","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:4308410","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4308410/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ther Adv Drug Saf","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W189413392","https://openalex.org/W1500064345","https://openalex.org/W1518621098","https://openalex.org/W1876689945","https://openalex.org/W1987041556","https://openalex.org/W1992540616","https://openalex.org/W1994385134","https://openalex.org/W2005134750","https://openalex.org/W2016401067","https://openalex.org/W2020794407","https://openalex.org/W2033494215","https://openalex.org/W2035228122","https://openalex.org/W2038150965","https://openalex.org/W2039105527","https://openalex.org/W2045549224","https://openalex.org/W2046381118","https://openalex.org/W2049965759","https://openalex.org/W2052553886","https://openalex.org/W2053997528","https://openalex.org/W2062895901","https://openalex.org/W2065042825","https://openalex.org/W2065301637","https://openalex.org/W2071720897","https://openalex.org/W2082700192","https://openalex.org/W2099478180","https://openalex.org/W2132632453","https://openalex.org/W2157428360","https://openalex.org/W2333507299","https://openalex.org/W4237732080","https://openalex.org/W4248307879","https://openalex.org/W4301519927"],"related_works":["https://openalex.org/W1966828315","https://openalex.org/W2257840139","https://openalex.org/W1525550968","https://openalex.org/W2038150965","https://openalex.org/W2000799601","https://openalex.org/W2093337999","https://openalex.org/W2580334472","https://openalex.org/W2281913645","https://openalex.org/W2982803386","https://openalex.org/W2032337693"],"abstract_inverted_index":{"Ezogabine":[0],"is":[1],"an":[2,18,35],"antiepileptic":[3],"medication":[4],"approved":[5],"in":[6,72,169],"June":[7],"2011":[8],"by":[9],"the":[10,90,103,119,133,137,149,170],"US":[11],"Food":[12],"and":[13,27,47,95,125,128,140,148,165],"Drug":[14],"Administration":[15],"(FDA)":[16],"as":[17],"adjunctive":[19],"treatment":[20,38],"for":[21,64,142,154],"partial":[22],"seizures.":[23],"Minimal":[24],"drug":[25,49],"interactions":[26],"a":[28,106,114],"novel":[29],"mechanism":[30],"of":[31,123,136,144],"action":[32],"made":[33],"ezogabine":[34,76,111],"appealing":[36],"new":[37],"option.":[39],"However,":[40],"adverse":[41],"effects":[42],"reported":[43,121],"during":[44],"clinical":[45],"trials":[46,168],"following":[48],"approval":[50],"have":[51,151],"been":[52,62],"alarming.":[53],"A":[54,67],"Risk":[55],"Evaluation":[56],"Mitigation":[57],"Strategy":[58],"(REMS)":[59],"program":[60],"has":[61],"established":[63],"urinary":[65],"retention.":[66],"safety":[68,167],"alert":[69],"was":[70],"published":[71,152,162],"April":[73],"2013":[74],"warning":[75,117],"may":[77,172],"cause":[78],"retinal":[79],"pigment":[80],"abnormalities":[81],"and/or":[82],"blue-gray":[83],"discoloration,":[84],"most":[85],"notably":[86],"on":[87],"or":[88],"near":[89],"lips,":[91],"nail":[92],"beds,":[93],"sclera":[94],"conjunctiva":[96],"with":[97],"long-term":[98,166],"use.":[99],"In":[100],"October":[101],"2013,":[102],"FDA":[104,150],"announced":[105],"formal":[107],"label":[108],"change":[109],"to":[110,112],"include":[113],"black":[115],"boxed":[116],"emphasizing":[118],"previously":[120],"warnings":[122],"eye":[124],"skin":[126],"discoloration":[127],"permanent":[129],"vision":[130],"changes.":[131],"Given":[132],"unknown":[134],"nature":[135],"pathophysiology,":[138],"consequences":[139],"potential":[141],"reversibility":[143],"these":[145,177],"effects,":[146],"GlaxoSmithKline":[147],"recommendations":[153],"patients":[155],"currently":[156],"receiving":[157],"ezogabine.":[158],"Further":[159],"data":[160],"from":[161],"case":[163],"reports":[164],"future":[171],"lend":[173],"additional":[174],"insight":[175],"into":[176],"concerning":[178],"effects.":[179]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}